{"success":true,"data":{"pressRelease":{"id":"47832","rtpr_id":"nGNX6ctj6m","ticker":"ARTV","exchange":"NASDAQ","all_tickers":["ARTV"],"title":"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference","author":"Globe Newswire","published_at":"2026-05-28T12:00:01.644Z","article_body":"SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc.\n(Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to\ndevelop effective, safe and accessible cell therapies for patients with\ndebilitating autoimmune diseases, today announced that Artiva management will\nparticipate in a fireside chat at the 2026 Jefferies Global Healthcare\nConference in New York on Thursday, June 4, 2026, at 9:20 am EDT.\n\nTo access the audio webcast and subsequent archived recording of this and\nother company presentations, please visit the Investors\n(https://www.globenewswire.com/Tracker?data=lnyg3TnBqDNcY_bDCQIgsECQvoo-eqOql-BlRYMAsqu4snR4bmKHVLZS-DnraVP0MGQou9kHEV_fY7Ctn80HdHm4D9CSz_XiXCnzjVUJWYzZvIMl4V_OFQ9B69sg13lwBrFv1RCuylVIBOa4c8ODAI9V188m0G1Dhr4pr-Eshbo=)\nsection of Artiva’s website. The archived audio webcast will remain\navailable for replay on Artiva’s website for 90 days.\n\nAbout Artiva Biotherapeutics\nArtiva is a clinical-stage biotechnology company whose mission is to develop\neffective, safe and accessible cell therapies for patients with debilitating\nautoimmune diseases. Artiva’s lead program, AlloNK(®) (also known as\nAB-101), is an allogeneic, off-the-shelf, non-genetically modified,\ncryopreserved NK cell therapy candidate designed to enhance the\nantibody-dependent cellular cytotoxicity effect of monoclonal antibodies to\ndrive B-cell depletion. AlloNK is currently being evaluated in three ongoing\nclinical trials for the treatment of B-cell driven autoimmune diseases,\nincluding a company-sponsored basket trial across autoimmune diseases that\nincludes rheumatoid arthritis and Sjögren’s disease and an\ninvestigator-initiated basket trial in B-cell driven autoimmune diseases.\nArtiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in\nrefractory RA in 2026. Artiva was founded in 2019 as a spin out of GC Cell,\nformerly GC Lab Cell Corporation, a leading healthcare company in the Republic\nof Korea, pursuant to a strategic partnership granting Artiva exclusive\nworldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK\ncell manufacturing technology and programs.\n\nArtiva is headquartered in San Diego, California. For more information, please\nvisit www.artivabio.com.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Statements in this press\nrelease that are not statements of historical fact are forward-looking\nstatements. Such forward-looking statements include, without limitation,\nstatements regarding: expectations of Artiva regarding the potential benefits,\naccessibility, effectiveness, safety and design of AlloNK(®); Artiva's plan\nto initiate a registrational Phase 3 trial for AlloNK in 2026; and Artiva's\nparticipation in the 2026 Jefferies Global Healthcare Conference. These\nforward-looking statements are based on the beliefs of the management of\nArtiva as well as assumptions made by and information currently available to\nArtiva. Such statements reflect the current views of Artiva with respect to\nfuture events and are subject to known and unknown risks and uncertainties,\nincluding, without limitation, risks inherent in developing product candidates\nand risks related to the legal and regulatory framework for the industry. In\nlight of these risks and uncertainties, the events or circumstances referred\nto in the forward-looking statements may not occur. These and other factors\nthat may cause Artiva's actual results to differ from current expectations are\ndiscussed in Artiva's filings with the Securities and Exchange Commission (the\n“SEC”), including the section titled “Risk Factors” in Artiva's\nQuarterly Report on Form 10-Q for the quarter ended March 31, 2026. You are\ncautioned not to place undue reliance on these forward-looking statements,\nwhich speak only as of the date this press release is given. Except as\nrequired by law, Artiva undertakes no obligation to publicly update any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise.\n\nContacts\n\nInvestors\nNoopur Batsha Liffick, MPH\nNBL LifeSci Advisory LLC\nir@artivabio.com\n\n(https://www.globenewswire.com/Tracker?data=zpC5fIxEse9xFi2iSwGVNrsFs87lq_TPCZET8wMXUqtBGXMxuWjjzyUnBH15l-mfLHAzOOT6D_zR8z64Pp8bOg==)\nMedia\nJessica Yingling, Ph.D.\nLittle Dog Communications Inc.\njessica@litldog.com\n\nSource: Artiva Biotherapeutics, Inc.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0392544b-ecff-4590-9eed-59c934e1ba4d)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6ctj6m","title":"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference","author":"Globe Newswire","ticker":"ARTV","created":"2026-05-28T12:00:01.644Z","tickers":["ARTV"],"exchange":"NASDAQ","article_body":"SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc.\n(Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to\ndevelop effective, safe and accessible cell therapies for patients with\ndebilitating autoimmune diseases, today announced that Artiva management will\nparticipate in a fireside chat at the 2026 Jefferies Global Healthcare\nConference in New York on Thursday, June 4, 2026, at 9:20 am EDT.\n\nTo access the audio webcast and subsequent archived recording of this and\nother company presentations, please visit the Investors\n(https://www.globenewswire.com/Tracker?data=lnyg3TnBqDNcY_bDCQIgsECQvoo-eqOql-BlRYMAsqu4snR4bmKHVLZS-DnraVP0MGQou9kHEV_fY7Ctn80HdHm4D9CSz_XiXCnzjVUJWYzZvIMl4V_OFQ9B69sg13lwBrFv1RCuylVIBOa4c8ODAI9V188m0G1Dhr4pr-Eshbo=)\nsection of Artiva’s website. The archived audio webcast will remain\navailable for replay on Artiva’s website for 90 days.\n\nAbout Artiva Biotherapeutics\nArtiva is a clinical-stage biotechnology company whose mission is to develop\neffective, safe and accessible cell therapies for patients with debilitating\nautoimmune diseases. Artiva’s lead program, AlloNK(®) (also known as\nAB-101), is an allogeneic, off-the-shelf, non-genetically modified,\ncryopreserved NK cell therapy candidate designed to enhance the\nantibody-dependent cellular cytotoxicity effect of monoclonal antibodies to\ndrive B-cell depletion. AlloNK is currently being evaluated in three ongoing\nclinical trials for the treatment of B-cell driven autoimmune diseases,\nincluding a company-sponsored basket trial across autoimmune diseases that\nincludes rheumatoid arthritis and Sjögren’s disease and an\ninvestigator-initiated basket trial in B-cell driven autoimmune diseases.\nArtiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in\nrefractory RA in 2026. Artiva was founded in 2019 as a spin out of GC Cell,\nformerly GC Lab Cell Corporation, a leading healthcare company in the Republic\nof Korea, pursuant to a strategic partnership granting Artiva exclusive\nworldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK\ncell manufacturing technology and programs.\n\nArtiva is headquartered in San Diego, California. For more information, please\nvisit www.artivabio.com.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Statements in this press\nrelease that are not statements of historical fact are forward-looking\nstatements. Such forward-looking statements include, without limitation,\nstatements regarding: expectations of Artiva regarding the potential benefits,\naccessibility, effectiveness, safety and design of AlloNK(®); Artiva's plan\nto initiate a registrational Phase 3 trial for AlloNK in 2026; and Artiva's\nparticipation in the 2026 Jefferies Global Healthcare Conference. These\nforward-looking statements are based on the beliefs of the management of\nArtiva as well as assumptions made by and information currently available to\nArtiva. Such statements reflect the current views of Artiva with respect to\nfuture events and are subject to known and unknown risks and uncertainties,\nincluding, without limitation, risks inherent in developing product candidates\nand risks related to the legal and regulatory framework for the industry. In\nlight of these risks and uncertainties, the events or circumstances referred\nto in the forward-looking statements may not occur. These and other factors\nthat may cause Artiva's actual results to differ from current expectations are\ndiscussed in Artiva's filings with the Securities and Exchange Commission (the\n“SEC”), including the section titled “Risk Factors” in Artiva's\nQuarterly Report on Form 10-Q for the quarter ended March 31, 2026. You are\ncautioned not to place undue reliance on these forward-looking statements,\nwhich speak only as of the date this press release is given. Except as\nrequired by law, Artiva undertakes no obligation to publicly update any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise.\n\nContacts\n\nInvestors\nNoopur Batsha Liffick, MPH\nNBL LifeSci Advisory LLC\nir@artivabio.com\n\n(https://www.globenewswire.com/Tracker?data=zpC5fIxEse9xFi2iSwGVNrsFs87lq_TPCZET8wMXUqtBGXMxuWjjzyUnBH15l-mfLHAzOOT6D_zR8z64Pp8bOg==)\nMedia\nJessica Yingling, Ph.D.\nLittle Dog Communications Inc.\njessica@litldog.com\n\nSource: Artiva Biotherapeutics, Inc.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0392544b-ecff-4590-9eed-59c934e1ba4d)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-28T12:00:01.890641827Z","server_sent_at_ms":1779969601890},"received_at":"2026-05-28T12:00:02.118Z","source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302755/0/en/Artiva-Biotherapeutics-to-Participate-in-the-2026-Jefferies-Global-Healthcare-Conference.html"},"analysis":{"id":"37265","press_release_id":"47832","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Artiva Biotherapeutics announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.\n\nThe session is scheduled for Thursday, June 4, 2026, at 9:20 am EDT in New York.\n\nAn archived audio webcast of the presentation will be available on Artiva’s website for 90 days following the event.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance; no new data or catalysts disclosed."},"keyFigures":{},"quotedText":"Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT.","namedEntities":{"people":[{"name":"Noopur Batsha Liffick","role":"Investor Relations Contact"},{"name":"Jessica Yingling","role":"Media Contact"}],"products":["AlloNK","AB-101"],"companies":[{"name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV"},{"name":"Jefferies","relationship":"conference organizer"},{"name":"GC Cell","relationship":"technology licensor"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference participation announcement. No new clinical data, partnership, or financial disclosure. Standard investor relations activity."},"tickerRelevance":{"others":[],"primary":"ARTV"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_ir","sectorWeight":"biotech","householdBrandBoost":0}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Artiva Biotherapeutics announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.\n\nThe session is scheduled for Thursday, June 4, 2026, at 9:20 am EDT in New York.\n\nAn archived audio webcast of the presentation will be available on Artiva’s website for 90 days following the event.","key_figures":{},"named_entities":{"people":[{"name":"Noopur Batsha Liffick","role":"Investor Relations Contact"},{"name":"Jessica Yingling","role":"Media Contact"}],"products":["AlloNK","AB-101"],"companies":[{"name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV"},{"name":"Jefferies","relationship":"conference organizer"},{"name":"GC Cell","relationship":"technology licensor"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-28T12:08:35.697Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_ir","sectorWeight":"biotech","householdBrandBoost":0}},"durationMs":39223,"modelName":"george-droid-qwen-72b"}}